Determination of blood sample sensitivity
We extracted human blood samples 1 and 2 using a commercial blood
magnetic bead extraction kit produced by BioDetect (Xiamen)
Biotechnology Co., Ltd. and diluted them with a 10-fold gradient of 1X
TE to obtain 1 ng/µl and 0.1 ng/µl samples. Each sample was
independently tested five times, and the minimum detection limit of the
blood sample genome was 0.1 ng/µl, as shown in Figure 7A-F. Among them,
CYP2C19 * 2 in blood 1 sample was homozygous wild-type, CYP2C19 * 3 was
heterozygous, and CYP2C19 * 17 was homozygous wild-type; in blood 2
sample, CYP2C19 * 2 was heterozygous, CYP2C19 * 3 was homozygous, and
CYP2C19 * 17 was homozygous. We also detected 5 oropharyngeal samples
and 5 saliva samples. For the oropharyngeal swabs, both sides of the
mouth were gently sampled. The swabs with exfoliated oral cells were
placed in the sample release agent, and the samples were shaken and
mixed. For saliva, a collection tube was used; the sample was mixed with
the release agent in equal proportion and shaken evenly for detection.
The results for the oropharyngeal samples are shown in Figure S1A. Three
cases of CYP2C19 * 2 heterozygosity, one case of CYP2C19 * 2 homozygous
wild-type, one case of CYP2C19 * 2 homozygous mutation, five cases of
CYP2C19 * 3 homozygous wild-type and five cases of CYP2C19 * 17
homozygous wild-type were successfully detected. The results for the
saliva samples are shown in Figure S1B. Three cases of CYP2C19 * 2
heterozygosity, 2 cases of CYP2C19 * 2 homozygous wild-type, 1 case of
CYP2C19 * 3 heterozygosity, 4 cases of CYP2C19 * 3 homozygous wild-type
and 5 cases of CYP2C19 * 17 homozygous wild-type were successfully
detected. Specific single peaks at each site were accurately observed.